Regenerx Biopharmaceuticals Inc (RGRX)

$0.00 -0.17 (-99.60%)
Market Cap 1,000.00
Revenue (ttm) 80,000.00
Net Income (ttm) -1.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,162.50%
Debt to Equity Ratio 0.00
Volume 100
Avg Vol 2,264
Day's Range N/A - N/A
Shares Out 1.44M
Stochastic %K 0%
Beta 170.54
Analysts Strong Buy
Price Target $1.50

Company Profile

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceutical Group for the development and marketing of Tß4-related products; and HLB Therapeutics for the d...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 208 9191
Address:
15245 Shady Grove Road, Suite 470, Rockville, United States
FlGeezer
FlGeezer Aug. 19 at 1:49 AM
$RGRX long overdue
0 · Reply
dontu1dr
dontu1dr Aug. 14 at 4:10 PM
$RGRX this is kinda NEWS–Y https://www.biobookmedia.com/articles/6042 QUOTES: “Separately from the clinical trial for neurotrophic keratitis, HLB Therapeutics is also preparing to launch Phase 3 ARISE-4, a Phase 4 clinical trial targeting the indication for dry eye disease (DED). Currently, the company is in the stage of pre-coordinating the clinical protocol with the U.S. FDA through a Special Study Approval (SPA).” “The industry believes that if the SEER-2 results coincide with the resumption of ARISE-4, discussions regarding licensing out (technology export) with global pharmaceutical companies are highly likely to begin in earnest. In particular, the company has also established intellectual property (IP) defense mechanisms by preemptively securing patents related to the manufacturing process of RGN-259 eye drops in major countries.” THE DONKER
2 · Reply
dontu1dr
dontu1dr Aug. 5 at 5:29 PM
$RGRX $.17 print, on our way back to the surface...
1 · Reply
dontu1dr
dontu1dr Jul. 28 at 5:17 PM
$RGRX do a search: HLB테라퓨틱스 click tab: news set time frame to 1 month... and you'll find that: Mr Jin, largest owner of HLB Inc and former CEO of entire company, has been buying up HLB THERA like a mad dog... read the stats... Liverdrug getting approval wasn't ever the big play, and has been ongoing great hope for years and years... RGN 259 NK is the closest thing to immediate cash that can float the boat of HLB (couldn't resist the pun---HLB LIFEBOAT)... Eye market is way overdue for healing modality vs another "treatment" as major problems in the works if they can't start actually "healing the eyes".... Iatrogenic eye caused problem list is "impressive", except it's the list killing the eyes. FDA pro peptides, no secret... Now, it's just a matter of what big pharma is standing in the wings and what they are willing to pay. Mr Jinn seems very condident with his momo... Enjoy, THE DONK
1 · Reply
Tr5
Tr5 Jul. 24 at 9:17 PM
$RGRX FDAs peptide review list, things could get interesting in a hurry. CNN: The peptides under consideration this week are: -BPC-157, proposed for treating ulcerative colitis -KPV for wound healing and inflammatory conditions -TB-500 for wound healing -MOTS-c for obesity and osteoporosis -Emideltide for opioid withdrawal, chronic —insomnia and narcolepsy -Semax for certain neurological disorders Epitalon for insomnia
1 · Reply
ByeAndHold
ByeAndHold Jul. 24 at 5:57 PM
$RGRX https://www.nytimes.com/2026/07/23/well/peptides-fda-research.html?smid=nytcore-ios-share
0 · Reply
Tr5
Tr5 Jul. 21 at 2:42 PM
$RGRX July 20, 2026 Press Release from HLB Theraputics To our shareholders, We are pleased to announce that our U.S. subsidiary, ReGenTree, has concluded patient enrollment for the global Phase 3 clinical trial (SEER-2) of RGN-259, a treatment for neurotrophic keratopathy (NK). After a comprehensive review of the current enrollment status and clinical trial conditions, we determined that the patients enrolled as of July were sufficient to meet the protocol requirements for deriving clinical results; therefore, we decided to finalize enrollment without recruiting additional patients. Following the conclusion of enrollment, the study will proceed with dosing and follow-up observations in accordance with the protocol.
1 · Reply
dontu1dr
dontu1dr Jul. 17 at 5:18 PM
$RGRX https://www.press9.kr/news/articleView.html?idxno=79478 Approved 2026.07.15 09:52 DIRECT QUOTES: “Wayne State University: Combination of antibiotics with mice infected with Pseudomonas aeruginosa… Improvement in nerve density and length on day 7 of infection. Preclinical model distinct from neurotrophic keratitis… Mechanistic basis to aid interpretation of SEER-2 results.” “The paper assessed that it provided direct evidence that adjuvant Tβ4 treatment promotes corneal nerve regeneration in bacterial keratitis.” “The nerve regenerative effect is also related to the pathophysiology of neurotrophic keratitis, which is the target of RGN-259. Neurotrophic keratitis is a disease in which corneal nerve damage leads to a decline in sensation and wound healing ability, resulting in persistent epithelial defects or ulcers.” END QUOTES So, essentially Wayne State discovers PROOF that TB4 regenerates corneal NERVES… THAT’S GOOD NEWS isn’t it JJ??? THE DONKER
1 · Reply
12e456789o
12e456789o Jul. 13 at 7:31 PM
$RGRX HLB Thera - Current downtrend obviosly extended. What I do like is the black w4 (triangle) is properly located. Double positive divergence on RSI 5. Needs to turn pronto or the RGRX ship is probably sunk. JMO. GLTA.
1 · Reply
PenkeInvesting
PenkeInvesting Jun. 23 at 9:40 PM
Fundamental analysis of $RGRX (REGENERX BIOPHARMACEUTICALS INC) based on financial data and reported results. #RGRX
0 · Reply
Latest News on RGRX
No data available.
FlGeezer
FlGeezer Aug. 19 at 1:49 AM
$RGRX long overdue
0 · Reply
dontu1dr
dontu1dr Aug. 14 at 4:10 PM
$RGRX this is kinda NEWS–Y https://www.biobookmedia.com/articles/6042 QUOTES: “Separately from the clinical trial for neurotrophic keratitis, HLB Therapeutics is also preparing to launch Phase 3 ARISE-4, a Phase 4 clinical trial targeting the indication for dry eye disease (DED). Currently, the company is in the stage of pre-coordinating the clinical protocol with the U.S. FDA through a Special Study Approval (SPA).” “The industry believes that if the SEER-2 results coincide with the resumption of ARISE-4, discussions regarding licensing out (technology export) with global pharmaceutical companies are highly likely to begin in earnest. In particular, the company has also established intellectual property (IP) defense mechanisms by preemptively securing patents related to the manufacturing process of RGN-259 eye drops in major countries.” THE DONKER
2 · Reply
dontu1dr
dontu1dr Aug. 5 at 5:29 PM
$RGRX $.17 print, on our way back to the surface...
1 · Reply
dontu1dr
dontu1dr Jul. 28 at 5:17 PM
$RGRX do a search: HLB테라퓨틱스 click tab: news set time frame to 1 month... and you'll find that: Mr Jin, largest owner of HLB Inc and former CEO of entire company, has been buying up HLB THERA like a mad dog... read the stats... Liverdrug getting approval wasn't ever the big play, and has been ongoing great hope for years and years... RGN 259 NK is the closest thing to immediate cash that can float the boat of HLB (couldn't resist the pun---HLB LIFEBOAT)... Eye market is way overdue for healing modality vs another "treatment" as major problems in the works if they can't start actually "healing the eyes".... Iatrogenic eye caused problem list is "impressive", except it's the list killing the eyes. FDA pro peptides, no secret... Now, it's just a matter of what big pharma is standing in the wings and what they are willing to pay. Mr Jinn seems very condident with his momo... Enjoy, THE DONK
1 · Reply
Tr5
Tr5 Jul. 24 at 9:17 PM
$RGRX FDAs peptide review list, things could get interesting in a hurry. CNN: The peptides under consideration this week are: -BPC-157, proposed for treating ulcerative colitis -KPV for wound healing and inflammatory conditions -TB-500 for wound healing -MOTS-c for obesity and osteoporosis -Emideltide for opioid withdrawal, chronic —insomnia and narcolepsy -Semax for certain neurological disorders Epitalon for insomnia
1 · Reply
ByeAndHold
ByeAndHold Jul. 24 at 5:57 PM
$RGRX https://www.nytimes.com/2026/07/23/well/peptides-fda-research.html?smid=nytcore-ios-share
0 · Reply
Tr5
Tr5 Jul. 21 at 2:42 PM
$RGRX July 20, 2026 Press Release from HLB Theraputics To our shareholders, We are pleased to announce that our U.S. subsidiary, ReGenTree, has concluded patient enrollment for the global Phase 3 clinical trial (SEER-2) of RGN-259, a treatment for neurotrophic keratopathy (NK). After a comprehensive review of the current enrollment status and clinical trial conditions, we determined that the patients enrolled as of July were sufficient to meet the protocol requirements for deriving clinical results; therefore, we decided to finalize enrollment without recruiting additional patients. Following the conclusion of enrollment, the study will proceed with dosing and follow-up observations in accordance with the protocol.
1 · Reply
dontu1dr
dontu1dr Jul. 17 at 5:18 PM
$RGRX https://www.press9.kr/news/articleView.html?idxno=79478 Approved 2026.07.15 09:52 DIRECT QUOTES: “Wayne State University: Combination of antibiotics with mice infected with Pseudomonas aeruginosa… Improvement in nerve density and length on day 7 of infection. Preclinical model distinct from neurotrophic keratitis… Mechanistic basis to aid interpretation of SEER-2 results.” “The paper assessed that it provided direct evidence that adjuvant Tβ4 treatment promotes corneal nerve regeneration in bacterial keratitis.” “The nerve regenerative effect is also related to the pathophysiology of neurotrophic keratitis, which is the target of RGN-259. Neurotrophic keratitis is a disease in which corneal nerve damage leads to a decline in sensation and wound healing ability, resulting in persistent epithelial defects or ulcers.” END QUOTES So, essentially Wayne State discovers PROOF that TB4 regenerates corneal NERVES… THAT’S GOOD NEWS isn’t it JJ??? THE DONKER
1 · Reply
12e456789o
12e456789o Jul. 13 at 7:31 PM
$RGRX HLB Thera - Current downtrend obviosly extended. What I do like is the black w4 (triangle) is properly located. Double positive divergence on RSI 5. Needs to turn pronto or the RGRX ship is probably sunk. JMO. GLTA.
1 · Reply
PenkeInvesting
PenkeInvesting Jun. 23 at 9:40 PM
Fundamental analysis of $RGRX (REGENERX BIOPHARMACEUTICALS INC) based on financial data and reported results. #RGRX
0 · Reply
12e456789o
12e456789o Jun. 21 at 10:18 PM
$RGRX HLB Thera got a low enough print to put in a bottom on Friday. Could continue a little lower but looking for a turn soon.
0 · Reply
dontu1dr
dontu1dr Jun. 5 at 12:30 PM
$RGRX Another link to an article: HLB Chairman Jin Yang-gon Purchases Additional Shares of HLB Therapeutics and HLB Genex https://www.fntimes.com/html/view.php?ud=202606021602351123923defd0cc_18 Quotes: -Following his purchase of 10,974 shares of HLB Therapeutics on the 29th of last month, Chairman Jin bought an additional 25,000 shares on the 1st of this month. -As a result, Chairman Jin’s stock holdings increased to 291,692 shares of HLB Therapeutics -HLB Therapeutics is also scheduled to disclose the top-line results of its Phase 3 (SEER-2) clinical trial for 'RGN-259,' a candidate treatment for neurotrophic keratitis (NK). -"We will focus on enhancing the overall corporate value of the group by actively communicating to the market the approval events for key pipelines starting in July and the growth strategies of each affiliate." NOW CONSIDER THIS: Both g-tree and hlb thera always stated they would License Out the TB4 Eye… THUS: TB4 EYE license out it quickest way to float the HLB BOAT… Enjoy the read, THE DONKER
1 · Reply
dontu1dr
dontu1dr Jun. 4 at 10:38 PM
$RGRX HLB Chairman Jin Yang-gon Makes Additional Open Market Purchases of HLB Therapeutics and HLB Genex Shares https://www.newspim.com/news/view/2026060200057 Quote HLB Therapeutics is also scheduled to release top-line results from the Phase 3 clinical trial (SEER-2) of its neurotrophic keratitis (NK) treatment candidate, 'RGN-259 Jin bought quite a bit of shares lately and in the last year. THE DONKEr
1 · Reply
12e456789o
12e456789o May. 20 at 3:13 PM
$RGRX HLB Thera 2965 breached so the only way we don't head further down is a leading diagonal which are uncommon but possible. A cluster of corrective waves since October. This is my best guess - a move down to finally finish off the bear. Since black 4 was an irregular wave all the count needs is a close below 2638. Probably make a new low but doesn't have to. Tricky chart.
1 · Reply
12e456789o
12e456789o May. 17 at 10:08 PM
$RGRX Two things need to happen for HLB Thera's chart to stay impulsive. 1) Needs to head up now. 3090 was Friday close and overlap of blue 1 - 3070 close) -would likely turn the chart bearish. Absolute line in the sand is a close below 2965. 2) needs to eclipse April high close of 3980 before end of May. So bottom line - Needs to move up now and move up strong.
1 · Reply
dontu1dr
dontu1dr May. 8 at 1:51 AM
$RGRX As Paul Harvey would say "And now you know the rest of the story" https://www.press9.kr/news/articleView.html?idxno=76094 The Donker
0 · Reply
ByeAndHold
ByeAndHold May. 6 at 6:17 PM
$RGRX Shareholder Letter out by JJ today. Patient enrollment complete , with data results and readout be out by years end. No additional information.
0 · Reply
dontu1dr
dontu1dr Apr. 29 at 3:26 PM
$RGRX HERE’S why BIG PHARMA will get TB4 EYE rights: BIG PHARMA plans years ahead… (TB4 holy $$ grail): Wayne State and TB4/VIP https://research.wayne.edu/news/wayne-state-university-research-aims-to-reduce-diabetes-effect-on-vision-66357 https://pmc.ncbi.nlm.nih.gov/articles/PMC10669755/#sec4-biosensors-13-00974 Despite the prevalence of diabetic retinopathy, up to 70% of the 460+ million diagnosed diabetics worldwide present with signs of diabetic corneal complications HUGE MARKET TB4/VIP COMBO Grant in 2nd year: https://reporter.nih.gov/search/z7kwVkQAgkqkpsWD0HiBeA/project-details/11312728 The global diabetic eye disease market is experiencing significant growth, driven by an increasing prevalence of diabetes, an aging global population, and advancements in diagnostic and treatment technologies. The market is projected to grow from approximately USD 9.5 billion in 2024 to over USD 13.77 billion by 2030, growing at a CAGR of roughly 6.4% to 8.5% THE DONKER
0 · Reply
dontu1dr
dontu1dr Apr. 25 at 2:07 PM
$RGRX Might want to read the following article: https://www.eyeworld.org/2026/early-momentum-in-biologics-for-corneal-conditions/ Chamberlain: ReGenTree site investigator Pflugfelder: ***NOTE*** historically has been a LONG TERM ADVOCATE for TB4 EYE -do a little research on this!!! ENJOY the read, THE DONK
0 · Reply
12e456789o
12e456789o Apr. 23 at 10:26 PM
$RGRX HLB Thera - time to head up again. Blue Minor wave 4 looks complete with a .618 retrace after the big move up. Using bar chart to show the retrace. There should be 3 more large waves up to complete the sequence.
0 · Reply
TheMotleyMonk
TheMotleyMonk Apr. 15 at 4:49 PM
$RGRX Anyone heard anything from the bunker in New Jersey? Radio silence on all fronts. Not even an update to shareholders...even a "no news" update would be appreciated.
1 · Reply
12e456789o
12e456789o Apr. 10 at 6:52 AM
$RGRX HLB Thera looking good this week
0 · Reply